OTCMKTS:SLNCF

Silence Therapeutics (SLNCF) Stock Price, News & Analysis

Silence Therapeutics logo
$6.53 0.00 (0.00%)
As of 11/13/2026

About Silence Therapeutics Stock (OTCMKTS:SLNCF)

Advanced

Key Stats

Today's Range
$6.53
▼
$6.53
50-Day Range
$3.85
▼
$6.53
52-Week Range
$1.06
▼
$6.53
Volume
N/A
Average Volume
10,101 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Silence Therapeutics plc is a clinical-stage biotechnology company focused on developing medicines that use RNA interference (RNAi) to selectively reduce the production of disease-associated proteins. The company’s approach is designed to target messenger RNA before it is translated into proteins, potentially addressing conditions that are difficult to treat with conventional therapies.

Silence Therapeutics develops small interfering RNA (siRNA) medicines using its proprietary GalNAc-conjugated delivery technology and related RNAi platforms. Its investigational pipeline has included zerlasiran (formerly SLN360), which is designed to reduce lipoprotein(a), a genetically determined risk factor associated with cardiovascular disease, and divesiran (formerly SLN124), an RNAi therapy being studied for hematologic disorders involving excessive red blood cell production. These programs remain investigational and are not approved medicines.

Founded in the United Kingdom and headquartered in London, Silence Therapeutics has historically advanced its programs through internal research, clinical development and collaborations with pharmaceutical companies. Its development activities and clinical studies have been conducted across multiple international markets. Craig Tooman has served as the company’s chief executive officer. As a biotechnology company, Silence Therapeutics’ future depends on clinical results, regulatory decisions and its ability to develop or partner its RNAi candidates.

AI Generated. May Contain Errors.

Silence Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
2nd Percentile Overall Score

SLNCF MarketRank™: 
0.11118508655 of 5 stars

Silence Therapeutics scored higher than 2% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Silence Therapeutics.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Silence Therapeutics is -27.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Silence Therapeutics is -27.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Percentage of Shares Shorted

  • Short Interest Ratio / Days to Cover

    Silence Therapeutics has a short interest ratio ("days to cover") of 0.29, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Silence Therapeutics has recently decreased by 94.21%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Silence Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Silence Therapeutics does not have a long track record of dividend growth.

  • News Coverage This Week

    MarketBeat has tracked 1 news article for Silence Therapeutics this week, compared to 0 articles on an average week.
Receive SLNCF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Silence Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

SLNCF Stock News Headlines

I'm handing you this stock today
Elon doesn't own the chip inside his Teslas or Starlink dishes. He licenses it from one little known public company. Now he's planning 1,000,000 AI satellites in orbit, and every one could pay this company a royalty. Analyst Dylan says the window to get in closes around December 8th, before new money floods into the buildout.tc pixel
Merck KGaA to Spend $1.3bn on Silence Therapeutics
See More Headlines

SLNCF Stock Analysis - Frequently Asked Questions

Silence Therapeutics' stock was trading at $2.00 on January 1st, 2026. Since then, SLNCF shares have increased by 226.3% and is now trading at $6.5265.

Shares of SLNCF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
OTCMKTS:SLNCF
CIK
1479615
Fax
N/A
Employees
100
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
N/A
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

This page (OTCMKTS:SLNCF) was last updated on 11/13/2026 by MarketBeat.com Staff.
From Our Partners